EGFR and neoplasm: Combining other anti-cancer drugs including DOX (20 μg/mL), liposomes (1.5 μg/mL) and mAbs Bevacizumab (1 mg/mL) with anti-EGFR-iRGD VHHs significantly enhanced their penetration capability and tumor inhibiting activity in mice models (124).